Teladoc Health, Inc.

Day range

$6.20 – $6.39

Open

$6.28

Prev close

$6.32

Volume

2.48M

Market cap

$1.15B

Shares out

181.68M

P/E

—

P/S

0.46

P/B

0.88

P/FCF

5.95

ROE

-13.5%

ROA

-6.4%

Debt/Equity

0.76

Div yield

0.00%

As of Oct 22, 2026

• Executive leadershipSep 25, 2026

  Following Mr. Vandervoort's departure, Jonathan Dorfman, currently the Company's Senior Vice President, Securities & Corporate Law, will assume the role of Chief Legal Officer and Secretary of the Company.

• Executive leadershipAug 31, 2026

  Effective August 31, 2026, Teladoc Health, Inc. (the "Company") hired Michael Grasher as its Chief Financial Officer. Charles Divita, III, who served as the Company's interim principal financial officer, will continue as Chief Executive Officer.

• Board of directorsAug 13, 2026

  On August 10, 2026, Mr. David B. Snow, Jr. notified Teladoc Health, Inc. (the "Company") of his intention to retire from the Board effective as of September 30, 2026. Mr. Snow has been a director of the Company since 2014 and the Company thanks him for his dedicated service. Mr. Snow has indicated that he is retiring from the Board for personal reasons and not because of any disagreement with the Company on any matter.

• Board of directorsAug 3, 2026

  Effective August 3, 2026, the Board of Directors (the "Board") of Teladoc Health, Inc. (the "Company") increased the number of directors on the Board to ten and appointed Mark V. Anquillare as a director of the Company. Mr. Anquillare was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determined that Mr. Anquillare is an independent director within the meaning of the New York Stock Exchange listing standards and is an "audit committee financial expert" under Securities and Exchange Commission (the "SEC") and New York Stock Exchange rules.

• Board of directorsMar 30, 2026

  Effective March 30, 2026, the Board of Directors (the "Board") of Teladoc Health, Inc. (the "Company") increased the number of directors on the Board to nine and appointed Susan R. Salka as a director of the Company. Ms. Salka was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determined that Ms. Salka is an independent director within the meaning of the New York Stock Exchange listing standards and is an "audit committee financial expert" under Securities and Exchange Commission (the "SEC") and New York Stock Exchange rules.

• AMZNAmazon.Com Inc-0.95%
• AMWLAmerican Well Corporation-4.37%
• ZMZoom Communications, Inc. Class A Common Stock-0.45%
• ROKURoku, Inc. Class A Common Stock-0.93%
• CRSPCRISPR Therapeutics AG-1.20%
• DOCSDoximity, Inc.-0.86%
• PINSPinterest, Inc. Class A Common Stock-2.66%

Days to cover

8.9

Short interest

30.1M

Avg volume

3.37M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale
  positiveGlobeNewswire Inc.· Oct 21, 2026
• Teladoc (TDOC) Outperforms Broader Market: What You Need to Know
  negativeZacks Investment Research· Oct 19, 2026
• Teladoc (TDOC) Rises As Market Takes a Dip: Key Facts
  neutralZacks Investment Research· Oct 13, 2026
• Holafly lance Ultra, un forfait eSIM international intégrant des services dédiés à la santé et au bien-être
  neutralGlobeNewswire Inc.· Oct 13, 2026
• Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
  positiveZacks Investment Research· Oct 8, 2026